地舒单抗对绝经后骨质疏松合并糖尿病前期女性糖代谢影响:12个月多中心开放标签随机对照试验研究方案
本研究为12个月多中心开放标签随机对照试验,计划纳入346例绝经后骨质疏松合并糖尿病前期女性,按1:1随机接受皮下地舒单抗60 mg每6个月一次或口服阿仑膦酸钠70 mg每周一次。主要结局为基线至12个月糖化血红蛋白变化,旨在评估地舒单抗对糖代谢的影响。
要点
- 纳入绝经后骨质疏松合并糖尿病前期女性,随机接受地舒单抗或阿仑膦酸钠治疗12个月。
- 主要结局为基线至12个月糖化血红蛋白水平变化。
- 次要结局包括空腹及2小时血糖、血清胰岛素、C肽、胰岛素敏感性变化及研究结束时2型糖尿病发生率。
核心结论
- 本研究旨在提供地舒单抗对绝经后骨质疏松合并糖尿病前期女性糖代谢疗效的证据,其结果可能为地舒单抗在高危人群中预防2型糖尿病的潜力提供见解。
研究设计与样本
- 12个月多中心、开放标签、随机对照试验,计划纳入346例绝经后骨质疏松合并糖尿病前期女性,按1:1随机分组。
- 骨质疏松定义为世界卫生组织(WHO)标准:双能X线吸收法(DXA)测得骨密度T值≤-2.5。
- 糖尿病前期定义为满足以下任一条件:空腹血糖100-125 mg/dL,或2小时血糖140-199 mg/dL,或糖化血红蛋白(HbA1c)5.7-6.4%。
关键数值与推荐
- 干预组:皮下注射地舒单抗60 mg,每6个月一次,持续12个月。
- 对照组:口服阿仑膦酸钠70 mg,每周一次,持续12个月。
- 主要结局:基线至12个月HbA1c水平变化。
- 次要结局:基线至12个月空腹及2小时血糖、血清胰岛素、C肽、胰岛素敏感性变化,以及研究结束时2型糖尿病发生率。
- 随访时间点:第3、6、9、12个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Participants with prediabetes are at a high risk of developing type 2 diabetes (T2D). Recent studies have suggested that blocking the receptor activator of nuclear factor-κB ligand (RANKL) may improve glucose metabolism and delay the development of T2D. However, the effect of denosumab, a fully human monoclonal antibody that inhibits RANKL, on glycemic parameters in the prediabetes population is uncertain. We aim to examine the effect of denosumab on glucose metabolism in postmenopausal women with osteoporosis and prediabetes. METHODS: This is a 12-month multicenter, open-label, randomized controlled trial involving postmenopausal women who have been diagnosed with both osteoporosis and prediabetes. Osteoporosis is defined by the World Health Organization (WHO) as a bone mineral density T score of ≤ - 2.5, as measured by dual-energy X-ray absorptiometry (DXA). Prediabetes is defined as (i) a fasting plasma glucose level of 100-125 mg/dL, (ii) a 2-hour plasma glucose level of 140-199 mg/dL, or (iii) a glycosylated hemoglobin A1c (HbA1c) level of 5.7-6.4%. A total of 346 eligible subjects will be randomly assigned in a 1:1 ratio to receive either subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg every week for 12 months. The primary outcome is the change in HbA1c levels from baseline to 12 months. Secondary outcomes include changes in fasting and 2-hour blood glucose levels, serum insulin levels, C-peptide levels, and insulin sensitivity from baseline to 12 months, and the incidence of T2D at the end of the study. Follow-up visits will be scheduled at 3, 6, 9, and 12 months. DISCUSSION: This study aims to provide evidence on the efficacy of denosumab on glucose metabolism in postmenopausal women with osteoporosis and prediabetes. The results derived from this clinical trial may provide insight into the potential of denosumab in preventing T2D in high-risk populations. TRIAL REGISTRATION: This study had been registered in the Chinese Clinical Trials Registry. REGISTRATION NUMBER: ChiCTR2300070789 on April 23, 2023. https://www.chictr.org.cn .
引用
- Wang Y, Jiang Y, Li J, et al. Effect of denosumab on glucose metabolism in postmenopausal osteoporotic women with prediabetes: a study protocol for a 12-month multicenter, open-label, randomized controlled trial. Trials. 2023. PMID: 38111052. doi:10.1186/s13063-023-07769-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。